Geron (GERN) Share-based Compensation (2010 - 2026)
Geron (GERN) posted Share-based Compensation of $4.9 million for Q1 2026, up 123.62% sequentially from -$20.8 million in Q4 2025, and down 33.81% YoY from $7.4 million in Q1 2025.
Geron (GERN) Share-based Compensation (2010 - 2026) Analysis & Trends
Geron has reported Share-based Compensation for 17 years, with the latest figure at $4.9 million in Q1 2026.
- Quarterly Share-based Compensation fell 33.81% year-over-year to $4.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$2.4 million (down 1404.35% YoY) and the FY2025 annual result came in at $88000.0, down 99.87% from the prior year.
- Share-based Compensation improved to $4.9 million in Q1 2026 per GERN's latest filing, from -$20.8 million in the prior quarter.
- Over five years, Share-based Compensation peaked at $20.8 million in Q3 2025 and troughed at -$24.3 million in Q4 2024.
- A 5-year average of $574470.6 and a median of $761000.0 in 2022 frame the typical range for Share-based Compensation.
- The sharpest annual moves came in 2023 and 2024: Share-based Compensation soared 52400.0% in 2023, then sank 649.3% in 2024.
- Over 5 years, Share-based Compensation stood at -$3.6 million in 2022, then soared by 221.72% to $4.4 million in 2023, then tumbled by 649.3% to -$24.3 million in 2024, then grew by 14.25% to -$20.8 million in 2025, then surged by 123.62% to $4.9 million in 2026.
- According to Business Quant data, Share-based Compensation over the past three periods registered $4.9 million, -$20.8 million, and $20.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.35 Bn | 131.49 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 86.24 Bn | 78.25 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 65.26 Bn | 60.08 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.83 Bn | 53.69 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 42.10 Bn | 37.00 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.68 Bn | 28.37 Bn | 992.69 Mn | 86.63 Mn |
| 7 | BioNTech SE | 27.95 Bn | 9.56 Bn | 668.28 Mn | 28.05 Mn |
| 8 | Insmed | 27.50 Bn | 26.34 Bn | 358.27 Mn | 41.25 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.44 Bn | - | - |
| 10 | Geron | 1.03 Mn | -299.82 Mn | - | 4.95 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.95 Mn |
| Jun 30, 2026 | 4.95 Mn |
| Mar 31, 2026 | 4.91 Mn |
| Mar 31, 2026 | 4.91 Mn |
| Dec 31, 2025 | -20.80 Mn |
| Dec 31, 2025 | -20.80 Mn |
| Sep 30, 2025 | 20.85 Mn |
| Sep 30, 2025 | 20.85 Mn |
| Jun 30, 2025 | -7.38 Mn |
| Jun 30, 2025 | -7.38 Mn |
| Mar 31, 2025 | 7.42 Mn |
| Mar 31, 2025 | 7.42 Mn |
| Dec 31, 2024 | -24.26 Mn |
| Dec 31, 2024 | -24.26 Mn |
| Sep 30, 2024 | 300,000.00 |
| Sep 30, 2024 | 300,000.00 |
| Jun 30, 2024 | 16.37 Mn |
| Jun 30, 2024 | 16.37 Mn |
| Mar 31, 2024 | 92,000.00 |
| Mar 31, 2024 | 92,000.00 |